Prognosis of parkinson disease. Risk of dementia and mortality: The rotterdam study

Archives of Neurology

Volumn 62, Issue 8, 2005, Pages 1265-1269

  De Lau, Lonneke M L ^a   Schipper, C Maarten A ^a   Hofman, Albert ^a   Koudstaal, Peter J ^a   Breteler, Monique M B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL EXAMINATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMENTIA; DISEASE DURATION; EVALUATION; FEMALE; FOLLOW UP; GENE FREQUENCY; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL INFORMATION; MEDICAL RECORD; MORTALITY; OUTCOMES RESEARCH; PARKINSON DISEASE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT;

AGED; COHORT STUDIES; COMORBIDITY; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 23844437947     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.8.1265     Document Type: Article

References (25)

1. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63:1240-1244.
2. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology. 2000;54:1272-1276.
3. Huang X, Chen PC, Poole C. APOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004;62:2198-2202.
4. Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62:2005-2009.
5. Koller WC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol. 1995;37:242-245.
6. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics. 2002;79:458-461.
7. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology. 1995;45:2143-2146.
8. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education: the Rotterdam study. BMJ. 1995;310:970-973.
9. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22:575-580.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
11. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord. 2004;19:1043-1049.
12. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387-392.
13. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol. 1995;52:695-701.
14. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708-1713.
15. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
16. Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62:937-942.
17. Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-1316.
18. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology. 2001;57:2278-2282.
19. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol. 1997;54:260-264.
20. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67:300-307.
21. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996;46:1044-1050.
22. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival: a population-based study. Arch Neurol. 2000;57:507-512.
23. Berger K, Breteler MM, Helmer C, et al. Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11, suppl 5):S24-S27.
24. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand. 2004;110:118-123.
25. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 2003;60:91-96.